These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31726882)

  • 1. The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD.
    Kalantar-Zadeh K; Hollenbeak CS; Arguello R; Snyder S; Ashfaq A
    J Med Econ; 2020 Mar; 23(3):308-315. PubMed ID: 31726882
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.
    Nuijten M; Andress DL; Marx SE; Sterz R
    Curr Med Res Opin; 2009 May; 25(5):1221-34. PubMed ID: 19335321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model.
    Nuijten M; Andress DL; Marx SE; Curry AS; Sterz R
    Clin Drug Investig; 2010; 30(8):545-57. PubMed ID: 20586517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A; Marshall TS; Khan SS; Johns B
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-Release Calcifediol: A Data Journey from Phase 3 Studies to Real-World Evidence Highlights the Importance of Early Treatment of Secondary Hyperparathyroidism.
    Merante D; Schou H; Morin I; Manu M; Ashfaq A; Bishop C; Strugnell S
    Nephron; 2024; 148(10):657-666. PubMed ID: 38657576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients.
    Germain MJ; Paul SK; Fadda G; Broumand V; Nguyen A; McGarvey NH; Gitlin MD; Bishop CW; Csomor P; Strugnell S; Ashfaq A
    BMC Nephrol; 2022 Nov; 23(1):362. PubMed ID: 36368937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis.
    Zhang Z; Cai L; Wu H; Xu X; Fang W; He X; Wang X; Li X
    Front Public Health; 2021; 9():712027. PubMed ID: 34368073
    [No Abstract]   [Full Text] [Related]  

  • 8. [Extended release calcifediol and paricalcitol in the treatment of secondary hyperparathyroidism: a network meta-analysis of indirect comparison].
    Franchi M; Galassi A; Corrao G
    G Ital Nefrol; 2023 Feb; 40(1):. PubMed ID: 36883925
    [No Abstract]   [Full Text] [Related]  

  • 9. Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis.
    Franchi M; Gunnarsson J; Gonzales-Parra E; Ferreira A; Ström O; Corrao G
    J Clin Endocrinol Metab; 2023 Oct; 108(11):e1424-e1432. PubMed ID: 37235771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness and Estimated Health Benefits of Treating Patients with Vitamin D in Pre-Dialysis.
    Snyder S; Hollenbeak CS; Kalantar-Zadeh K; Gitlin M; Ashfaq A
    Forum Health Econ Policy; 2020 Mar; 23(1):. PubMed ID: 32134730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol.
    Fadda G; Germain MJ; Broumand V; Nguyen A; McGarvey N; Gitlin M; Bishop CW; Ashfaq A
    Am J Nephrol; 2021; 52(10-11):798-807. PubMed ID: 34818216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
    Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective.
    Menezes FG; Abreu RM; Itria A
    J Bras Nefrol; 2016; 38(3):313-319. PubMed ID: 27737389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS; Karagiannis PC; Peyerl FW
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
    Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
    J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease.
    Galassi A; Bellasi A; Ciceri P; Pivari F; Conte F; Cozzolino M
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1073-1084. PubMed ID: 28846459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected].
    Nuijten M; Roggeri DP; Roggeri A; Novelli P; Marshall TS
    Clin Drug Investig; 2015 Apr; 35(4):229-38. PubMed ID: 25724153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis.
    Piñera-Haces C; Izquierdo-Ortiz MJ; Martín-de Francisco ÁL; García-Unzueta MT; López-Hoyos M; Toyos C; Allende N; Quintela E; Arias M
    Nefrologia; 2013 Jan; 33(1):77-84. PubMed ID: 23364629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease.
    Strugnell SA; Csomor P; Ashfaq A; Bishop CW
    Kidney Dis (Basel); 2023 May; 9(3):206-217. PubMed ID: 37497207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
    Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.